Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NVS vs PFE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 3 – 3 PFE Matrix Metrics: NVS 7 – 3 PFE

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Pfizer Inc. (PFE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas PFE carries 52.3/100 (HOLD) at $28.45 (9.8x Forward P/E, 29.1% operating margin).

  • Composite vs. Pillar Nuance: While PFE currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 29.1% operating margin) and revenue trajectory (+4.7% vs. -0.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs PFE
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$159.20
-0.62% 1D
Market Cap $303.1B
TTM Revenue $40.5B
Forward P/E 16.1x
Beta / 30D Vol 0.31β · 26% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 33.0 Fund 38.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 55
RSI-14: 55.1 · SMA20: $159.38 · SMA50: $149.57
PFE NYSE
Pfizer Inc.
Pharmaceutical Preparations
$28.45
-1.42% 1D
Market Cap $164.7B
TTM Revenue $63.6B
Forward P/E 9.8x
Beta / 30D Vol 0.18β · 24% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 32.0 Fund 54.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.7 · SMA20: $29.68 · SMA50: $28.82

6-Pillar Scorecard Institutional Category Breakdown (NVS 3 – 3 PFE)

Columns: Metric · NVS · PFE
1. Valuation Multiples PFE
Forward P/E 16.1x 9.8x
Trailing P/E 30.6x 41.3x
PEG Ratio 3.82x 8.83x
EV / Revenue 7.5x 3.5x
2. Growth & Scale NVS
Revenue Growth (YoY) +4.7% -0.4%
Earnings Growth (YoY) -68.8% -9.7%
TTM Revenue (USD) $40.5B $63.6B
Market Cap $303.1B $164.7B
3. Profitability & Quality NVS
Gross Margin 75.2% 74.9%
Operating Margin 34.0% 29.1%
Net Profit Margin 17.5% 6.3%
Return on Equity (ROE) 24.3% 4.5%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $11.8B
Cash Flow Margin 42.0% EBITDA Mgn 18.5%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $60.8B Net Debt (0.70x D/E)
Dividend Yield 2.95% 7.46%
5. Options & Positioning PFE
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 16.9% (6th %ile) 27.7% (33rd %ile)
Put/Call OI Skew Thin ADR Chain 0.62x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat PFE
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 45.8% of Rev ($29.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (7) vs PFE (3)
Institutional Metric NVS PFE Criterion Row Edge
Market Capitalization
Scale
$303.1B $164.7B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 41.3x Lower Multiple NVS
Forward P/E Ratio
Valuation
16.1x 9.8x Lower Multiple PFE
Revenue Growth (YoY)
Growth
+4.7% -0.4% Higher Growth NVS
Operating Margin (TTM)
Profitability
34.0% 29.1% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 6.3% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 4.5% Higher ROE NVS
52-Week Range Position
Momentum
76% ($123–$170) 62% ($24–$31) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 26% Vol 0.18β · 24% Vol Lower Realized Risk PFE
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 52.3 / 100 (HOLD) Higher Composite PFE
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $63.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 74.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.82x PEG · 7.5x EV/Rev 8.83x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $11.8B ($60.8B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +9.35 pp
NVS: +5.99% · PFE: -3.36%
3M Horizon PFE +1.43 pp
NVS: -0.69% · PFE: +0.74%
6M Horizon PFE +5.05 pp
NVS: +5.82% · PFE: +10.87%
1Y Horizon NVS +7.76 pp
NVS: +21.29% · PFE: +13.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs PFE. Trailing 12-month operating profitability (NVS 34.0% vs PFE 29.1%) and valuation multiples (NVS 16.1x vs PFE 9.8x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.1x
PFE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$63.6B
Gross Margin74.9%
Op. Margin29.1%
ROE / Fwd P/E4.5% · 9.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PFE CONSOLIDATION
53d in phase · OBV DISTRIBUTION
Current IV 27.7%
IV Percentile 33rd %ile
Put/Call OI Skew 0.62x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PFE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $28.86 · IV 25.6%

PFE Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,886)

Compare $2,886 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 25.6% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $29 / $30 Bull Call Spread

Buy 2x $29C · Sell 2x $30C · 31d

Net Entry $84 Debit
T+5d @ +5% Move +$52 (+62%)
Max Risk / Buffer $84 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $27 / $25 Bull Put Spread

Sell 2x $27P · Buy 2x $25P · 59d

Net Entry $58 Credit
Max Credit / Yield +$58 (+17.0% RoM)
Max Risk / Buffer -7.4% Cushion ($342 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 24 $27P / $29-$31C Seagull

Sell 1x $27P · Buy 1x $29/$31C · 37d

Net Entry $40 Debit
T+5d @ +5% Move +$66 (+14.3% RoM)
Max Risk / Buffer -6.4% Put Cushion ($459 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $303.1B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
PFE Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $164.7B market capitalization and 29.1% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($29.1B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs PFE Key Questions & Quantitative Answers

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Pfizer Inc. (PFE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas PFE carries 52.3/100 (HOLD) at $28.45 (9.8x Forward P/E, 29.1% operating margin). Composite vs. Pillar Nuance: While PFE currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 29.1% operating margin) and revenue trajectory (+4.7% vs. -0.4% YoY).

NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with PFE at -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $63.6B for PFE. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($29.1B) (0 disclosures) for PFE.

PFE screens cheaper on headline valuation multiples. NVS trades at 16.1x Forward P/E, 30.6x Trailing P/E, 3.82x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas PFE trades at 9.8x Forward P/E, 41.3x Trailing P/E, 8.83x PEG, and 3.5x EV/Revenue (18.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus PFE (4.5% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 26% Vol realized risk). By comparison, PFE carries 27.7% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.18β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.